Statin therapy and the development of cerebral amyloid angiopathy—A rodent in vivo approach

1Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

Abstract

Background: Cerebral amyloid angiopathy (CAA) is characterized by vascular deposition of amyloid β (Aβ) with a higher incidence of cerebral microbleeds (cMBs) and spontaneous hemorrhage. Since statins are known for their benefit in vascular disease we tested for the effect on CAA. Methods: APP23-transgenic mice received atorvastatin-supplemented food starting at the age of eight months (n = 13), 12 months (n=7), and 16 months (n=6), respectively. Controls (n = 16) received standard food only. At 24 months of age cMBs were determined with T2*-weighted 9.4T magnetic resonance imaging and graded by size. Results: Control mice displayed an average of 35 ± 18.5 cMBs (mean ± standard deviation), compared to 29.3 ± 9.8 in mice with eight months (p=0.49), 24.9 ± 21.3 with 12 months (p=0.26), and 27.8 ± 15.4 with 16 months of atorvastatin treatment (p = 0.27). In combined analysis treated mice showed lower absolute numbers (27.4 ± 15.6, p = 0.16) compared to controls and also after adjustment for cMB size (p=0.13). Conclusion: Despite to a non-significant trend towards fewer cMBs our results failed to provide evidence for beneficial effects of long-term atorvastatin treatment in the APP23-transgenic mouse model of CAA. A higher risk for bleeding complications was not observed.

Cite

CITATION STYLE

APA

Reuter, B., Venus, A., Grudzenski, S., Heiler, P., Schad, L., Staufenbiel, M., … Fatar, M. (2016). Statin therapy and the development of cerebral amyloid angiopathy—A rodent in vivo approach. International Journal of Molecular Sciences, 17(1). https://doi.org/10.3390/ijms17010126

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free